Intracerebral hemorrhage (ICH) is the most devastating form of stroke, conferring the highest morbidity and mortality of any stroke subtype.1 To date, most interventions have targeted hematoma expansion. However, ICH expansion occurs early after onset and only in a subset of patients. Therefore, treatments can only be given in the hyperacute setting and, even if successful, will end up benefiting only a minor proportion of patients. In contrast, secondary injury and the development of perihematomal edema (PHE) contribute to further tissue damage and neurologic deterioration over an extended window of hours to days. Therefore, therapies that prevent or reverse such damage could be given more easily and widely.
Sheth KN, Rosand J. Targeting the Immune System in Intracerebral Hemorrhage. JAMA Neurol. 2014;71(9):1083–1084. doi:10.1001/jamaneurol.2014.1653
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: